Science Explorer Back to mapMap
Discussion
Topic · Pathology and Forensic Medicine

Chemotherapy-induced organ toxicity mitigation

Chemotherapy-induced organ toxicity mitigation is a research topic within Pathology and Forensic Medicine. Science Explorer counts 11k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the mechanisms of cisplatin-induced nephrotoxicity, including oxidative stress, apoptosis, inflammation, and mitochondrial dysfunction. It also explores various renoprotective strategies and potential interventions to mitigate kidney injury caused by cisplatin. The research covers a wide range of topics such as the role of specific antioxidants, inflammatory pathways, and cellular mechanisms involved in chemotherapy-induced kidney damage.

  • Cisplatin
  • Nephrotoxicity
  • Renoprotective Strategies
  • Oxidative Stress
  • Apoptosis
  • Inflammation
  • Mitochondrial Dysfunction
  • Antioxidants
  • Chemotherapy
  • Kidney Injury
Research works
11k
fractional, since 1950
In the world top 10%
1.1k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+17%
the tick is no change
Largest producer
China
28% of the 10 largest, 2022-now
Chemotherapy-induced organ toxicity mitigation

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Chemotherapy-induced organ toxicity mitigation research?

By volume, China and the United States publish the most (541 and 292 works in 2022-now).

By volume, 2022-now

  1. 1 China 541 works
  2. 2 United States 292 works
  3. 3 Egypt 232 works
  4. 4 India 199 works
  5. 5 Türkiye 194 works
  6. 6 Iran 153 works
  7. 7 Japan 138 works
  8. 8 Saudi Arabia 93 works
  9. 9 Iraq 62 works
  10. 10 South Korea 52 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 27.7%United States: 14.9%Egypt: 11.8%India: 10.2%6 others listed: 35.4%28%largest
China541 · 27.7%United States292 · 14.9%Egypt232 · 11.8%India199 · 10.2%6 others listed693 · 35.4%

Shares of the rows listed above, not of the whole node.

Which institutions lead Chemotherapy-induced organ toxicity mitigation research?

By volume in 2022-now, Mansoura University publishes the most Chemotherapy-induced organ toxicity mitigation research, followed by Cairo University and Zagazig University.

By volume, 2022-now

  1. 1 Mansoura UniversityEgypt 25 works
  2. 2 Cairo UniversityEgypt 22 works
  3. 3 Zagazig UniversityEgypt 16 works
  4. 4 Tanta UniversityEgypt 15 works
  5. 5 Islamic Azad University, TehranIran 14 works
  6. 6 Nanjing Medical UniversityChina 14 works
  7. 7 Sun Yat-sen UniversityChina 13 works
  8. 8 Mashhad University of Medical SciencesIran 13 works
  9. 9 Alexandria UniversityEgypt 12 works
  10. 10 King Saud UniversitySaudi Arabia 12 works

Who are the leading researchers in Chemotherapy-induced organ toxicity mitigation?

The most-cited researchers publishing on Chemotherapy-induced organ toxicity mitigation include Guido Kroemer, Lesley A. Stewart and Hagop M. Kantarjian.

  1. 1 Guido Kroemer France 386k citations
  2. 2 Lesley A. Stewart United Kingdom 308k citations
  3. 3 Hagop M. Kantarjian United States 273k citations
  4. 4 Amirhossein Sahebkar Iran 258k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Chemotherapy-induced organ toxicity mitigation?

The most cited paper in Chemotherapy-induced organ toxicity mitigation is "Cisplatin in cancer therapy: Molecular mechanisms of action" (Shaloam R. Dasari, Paul Bernard Tchounwou, 2014), with 5,600 citations. Next come "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma" (4,813) and "Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer" (2,878).

Most cited papers
#PaperReleasedCitations
1 Cisplatin in cancer therapy: Molecular mechanisms of action Shaloam R. Dasari, Paul Bernard Tchounwou · European Journal of Pharmacology Open access 21 Jul 2014 5,600
2 Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine Open access 10 Jan 2007 4,813
3 Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer William Patrick McGuire, William J. Hoskins, Mark F. Brady et al. · New England Journal of Medicine Open access 4 Jan 1996 2,878
4 Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer Deborah Kay Armstrong, Brian N. Bundy, Lari B. Wenzel et al. · New England Journal of Medicine Open access 4 Jan 2006 2,644
5 Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems Oktay Tacar, Pornsak Sriamornsak, Crispin R. Dass · Journal of Pharmacy and Pharmacology 3 Aug 2012 2,482
All 99 most cited papers, with filters and sorting

Where is Chemotherapy-induced organ toxicity mitigation research done?

The largest centres of Chemotherapy-induced organ toxicity mitigation research in 2022-now are Beijing (China), Cairo (Egypt), Guangzhou (China) and Giza (Egypt). Among places with at least 20 works in it, it is an unusually large share of all research in Al Mansurah.

Largest cities, 2022-now

  1. 1 BeijingChina 53 works
  2. 2 CairoEgypt 52 works
  3. 3 GuangzhouChina 40 works
  4. 4 GizaEgypt 37 works
  5. 5 TehranIran 33 works
  6. 6 TokyoJapan 33 works
  7. 7 ShanghaiChina 32 works
  8. 8 RiyadhSaudi Arabia 30 works
  9. 9 NanjingChina 27 works
  10. 10 Al MansurahEgypt 27 works

Where it is the local speciality

  1. Al MansurahEG · 27.1 works21×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Chemotherapy-induced organ toxicity mitigation than the world average.

See Chemotherapy-induced organ toxicity mitigation on the map

Where is the best place to study Chemotherapy-induced organ toxicity mitigation?

Among universities, judged by research, Cairo University, Mansoura University and Atatürk University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.69%fractional works in this field (log) →share of work in the world top 10% →Atatürk UniversityGuangzhou University…Cairo UniversityMansoura University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Cairo UniversityEgypt 65.214.8%12.3×22 +30.3%
2Mansoura UniversityEgypt 60.08.1%24.0×25 +34.1%
3Atatürk UniversityTürkiye 57.732.1%13.2×11 -21.0%
4Guangzhou University of Chinese MedicineChina 56.224.1%15.6×9 +73.4%
5Anhui Medical UniversityChina 53.925.6%9.1×10 +43.8%
6Tanta UniversityEgypt 53.210.4%20.7×15 +54.0%
7Al-Azhar UniversityEgypt 53.120.7%13.7×12 -5.1%
8King Saud UniversitySaudi Arabia 51.519.0%5.5×12 -26.2%
9Beni-Suef UniversityEgypt 50.621.1%25.6×9 -11.1%
10Harvard UniversityUnited States 48.321.0%1.4×10 +23.4%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Chemotherapy-induced organ toxicity mitigation, country by country

Is Chemotherapy-induced organ toxicity mitigation research growing?

Output in 2022-2025 was 17% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Chemotherapy-induced organ toxicity mitigation.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Chemotherapy-induced organ toxicity mitigation as a percentage of every work published that year, 0.0088% in 2024.

still counting0.010%0.020%Chemotherapy-induced organ toxicity mitigation0.012% in 202519801990200020102020

Fractional works of Chemotherapy-induced organ toxicity mitigation over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Chemotherapy-induced organ toxicity mitigation10.4% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Chemotherapy-induced organ toxicity mitigation. Posts are plain text and can be reported.